Liquid biopsy could predict prognosis of glioblastoma, study suggests

A blood test that measures the amount of cfDNA in the blood – also known as a liquid biopsy – has been correlated with how patients will progress following a glioblastoma diagnosis. Within the study, which has been published in Clinical Cancer Research, researchers from the Abramson Cancer Center of the University of Pennsylvania (PA, USA) have demonstrated that individuals with a higher concentration of cfDNA have shorter progression-free survival than patients with less cfDNA. Additionally, the team also noted that cfDNA spikes in patients either at the time of, or just before, their disease progresses. They also revealed that...